ESMO 2023 | Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses the results of a study looking at real-world sacituzumab govitecan (SG) dosing and clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with SG as second-line or later treatment. 230 patients were included in the analysis and median real-world overall survival (rwOS) was 10.0 months, and median real world progression-free survival (rwPFS) was 3.8 months. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.